Oxxides, Inc Harriman, NY

Antimony Trioxide, Oxidative stress, 8OHdG

Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience
Cas9 Antibody Cas9 Cell Line Cas9 Enzyme Cas9 Lentivirus Cas9 Mrna Cas9 Nickase

Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Acute promyelocytic leukemia is a variant of acute myeloid leukemia characterised by t(15;17) and PML/RAR alfa fusion gene. The invention of the molecular pathogenesis has led to entitle all-trans retinoic acid (ATRA) as the primary focused remedy for acute leukemia. It’s often related to anthracycline-based chemotherapy with excessive response charges, however potential long-term sequelae together with therapy-related malignancies have been noticed.
Arsenic trioxide (ATO) was added to obviate these issues and investigational trials aimed to a brand new technique with the incorporation of arsenic trioxide (ATO) into preliminary remedy as an alternative of chemotherapy in chosen sufferers. ATRA plus ATO with out chemotherapy was the primary try to deal with low and intermediate-risk sufferers with APL. Our examine goals to explain a monocentric cohort of sufferers with newly recognized APL successfully handled with ATO plus ATRA underlying its efficacy along with the excessive grade of tolerability of this affiliation.
From January 2009 to December 2019 23 APL sufferers have been recognized and handled with ATO plus ATRA routine: 14 males and 9 females sufferers with a median age of 45 years (vary 18-72), for almost all intermediate threat (15 sufferers, 65%). The remedy was properly tolerated and all sufferers achieved molecular remission after a median time of three months (vary 1-6 months). All sufferers proceeded to consolidation section as outpatients, they maintained full molecular response at a median time of 44 months (vary 15-127) apart from 1 affected person.
All however one affected person are alive and in response at a median follow-up of 48 months (vary 9-141) with out late results. ATO plus ATRA routine exhibits benefits compared to chemotherapy; actually it allowed to deal with sufferers during which chemotherapy may even not be relevant and it didn’t present secondary hematological ailments. The affiliation of ATO to ATRA as chemo-free routine enabled to deal with APL even with out chemotherapy.

Investigation of the ameliorative results of baicalin in opposition to arsenic trioxide-induced cardiac toxicity in mice

Baicalin (BA), a form of flavonoids compound, comes from Scutellaria baicalensis Georgi (a form of perennial herb) and has useful results on the cardiovascular system by means of anti-oxidant, anti-inflammation, and anti-apoptosis actions. Nevertheless, the therapeutic results and latent mechanisms of BA on arsenic trioxide (ATO)-induced cardiac toxicity has not been reported. The current analysis was carried out to discover the results and mechanisms of BA on ATO-induced coronary heart toxicity.
Male Kunming mice have been handled with ATO (7.5 mg/kg) to induce cardiac toxicity. After the mice obtained ATO, BA (50 and 100 mg/kg) was administered for estimating its cardioprotective results. Statistical information demonstrated that BA remedy alleviated electrocardiogram abnormalities and pathological harm attributable to ATO.
BA may additionally result in restoration of CK and LDH actions to regular vary and trigger a lower in MDA ranges and ROS technology, augmentation of SOD, CAT, and GSH actions. We additionally discovered that BA prompted a discount within the expression of proinflammatory cytokines, akin to TNF-α and IL-6. Furthermore, BA attenuated ATO-induced apoptosis by selling the expression of Bcl-2 and suppressing the expression of Bax and caspase-3. TUNEL take a look at consequence demonstrated BA prompted obstacle of ATO-induced apoptosis.
Moreover, BA remedy suppressed the excessive expression of TLR4, NF-κB and P-NF-κB attributable to ATO. In conclusion, these outcomes point out that BA might alleviate ATO-induced cardiac toxicity by restraining oxidative stress, apoptosis, and irritation, and its mechanism can be related to the inhibition of the TLR4/NF-κB signaling pathway.

Comparative Analysis of Mineral Trioxide Mixture Obturation Utilizing 4 Totally different Methods-A Laboratory Research

This examine aimed to check the density of mineral trioxide combination (MTA) as a root canal filling materials within the apical 5 mm of synthetic root canals. Forty clear acrylic blocks with 30-degree curved canals have been instrumented and allotted into 4 compaction method teams (n = 10): Lawaty (hand recordsdata); gutta-percha (GP) factors; auger (nickel-titanium rotary recordsdata in reverse mode); and plugger method. Crammed canals have been weighed after setting the MTA to calculate distinction in mass.
Two postoperative radiographs in contrast radiopacity by measuring luminance variations at 0.5 mm, 1 mm, 2 mm, Three mm, four mm, and 5 mm from the basis apex. Obturation time was measured utilizing a digital chronometer. The importance stage was set to p < 0.05. The plugger group had a decrease mass. Relative luminance was considerably greater for the Lawaty group than the plugger group in any respect examined apical ranges.
The relative luminance of the auger and GP teams have been considerably greater than the plugger group at depths between 0.5 mm and a couple of mm. Relative luminance was highest for the Lawaty method in any respect depths between 0.5 mm and four mm. The Lawaty method group was related to elevated obturation time in contrast with pluggers. Compacting MTA in curved canals with the Lawaty method has the best mass and radiopacity however requires extra time.
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Arsenic trioxide encapsulated liposomes prepared via copper acetate gradient loading method and its antitumor efficiency

In this study, arsenic trioxide (ATO) was encapsulated in liposomes via copper acetate (Cu(OAc)2) gradients and high entrapment efficiency of over 80% was obtained. The average particle size and the zeta-potential of the liposomes were detected to be 115.1 ± 29.1 nm and -21.97 ± 0.6 mV, respectively.
The TEM images showed rod-like precipitates in the inner aqueous phase, which was supposed be due to the formation of insoluble ATO-Cu complex. The in vitro drug release of ATO-Cu liposomes exhibited a sustained release over 72 h, and the release rates decreased with the increase of the pH of release media. Pharmacokinetic and tissue distribution studies of ATO liposomes showed significantly reduced plasma clearance rate, increased AUC0-12 h and T1/2, and improved tumor distribution of As compared to iv administration of ATO solution.
The anti-tumor effect of ATO loaded liposomes to S180 tumor-bearing mice was significantly improved with a tumor inhibition rate of 61.2%, meanwhile the toxicity of encapsulated ATO was greatly decreased.

Molybdenum silicide, 99.5%
GX2864-250 250
EUR 268.8

Molybdenum(VI) oxide, 99.9%
GX8007-100G 100 g
EUR 156

Molybdenum(VI) oxide, 99.9%
GX8007-1KG 1 kg
EUR 466.8

Molybdenum(VI) oxide, 99.9%
GX8007-250G 250 g
EUR 219.6

Molybdenum(VI) oxide, 99.0%
GX6266-250 250
EUR 119.1

Molybdenum(VI) oxide, 99.0%
GX6266-500 500
EUR 192.2

Molybdenum(VI) oxide, 99.9%
GX8007-1 1
EUR 355.8

Molybdenum(VI) oxide, 99.9%
GX8007-100 100
EUR 99.7

Molybdenum(VI) oxide, 99.9%
GX8007-250 250
EUR 151.8

Molybdenum Foil 0.5mm, 99.95%
GX9163-100 100
EUR 231.3

Molybdenum(IV) oxide, 99+%
GX0932-100 100
EUR 208.6

Molybdenum(IV) oxide, 99+%
GX0932-25 25
EUR 93.4

Molybdenum Foil 0.2mm, 99.95%
GX1246-100 100
EUR 164.5

Molybdenum Foil 0.3mm, 99.95%
GX1962-100 100
EUR 203.6

Molybdenum Foil 0.1mm, 99.95%
GX2552-100 100
EUR 132.6

Molybdenum Foil 1.0mm, 99.9+%
GX9760-100 100
EUR 309.6

Molybdenum Foil 1.0mm, 99.9+%
GX9760-150 150
EUR 313

Molybdenum Sheet 2.5mm, 99.9+%
GX3862-100 100
EUR 301.3

Molybdenum Foil 0.15mm, 99.95%
GX4416-100 100
EUR 140.2

Molybdenum Sheet 3mm, 99.9+%
GX6521-100 100
EUR 485.6

Molybdenum Foil 0.25mm, 99.9+%
GX8943-100 100
EUR 120.5

Molybdenum Foil 0.25mm, 99.9+%
GX8943-150 150
EUR 182.5

Molybdenum Foil 0.25mm, 99.9+%
GX8943-50 50
EUR 98

Molybdenum Sheet 2mm, 99.9+%
GX9338-100 100
EUR 264

Molybdenum Sheet 1.5mm, 99.9+%
GX9615-100 100
EUR 215.1

Molybdenum Foil 0.025mm, 99.9+%
GX9911-100 100
EUR 177.5

Molybdenum Foil 0.025mm, 99.9+%
GX9911-150 150
EUR 220.1

Molybdenum Foil 0.025mm, 99.9+%
GX9911-50 50
EUR 104

Molybdenum(II) carbide, 99.5+%
GX1923-100 100
EUR 129.6

Molybdenum(II) carbide, 99.5+%
GX1923-250 250
EUR 255.7

Molybdenum(IV) sulfide, 98+%
GX2871-1 1
EUR 241.2

Molybdenum(IV) sulfide, 98+%
GX2871-250 250
EUR 116.1

Molybdenum(IV) sulfide, 98+%
GX2871-500 500
EUR 146.2

ICP Std Molybdenum 1000ug/mL in H2O
PMO2C1L 1L
EUR 616.24

ICP Std Molybdenum 10000ug/mL in H2O
RPMO4B7 250ML
EUR 236.31

ICP Std Molybdenum 1000ug/mL in 1% HCl
PMO2A11 100ML
EUR 134.48

ICP Std Molybdenum 1000ug/mL in 2% NH4OH
PMO2B7 250ML
EUR 213.6

ICP Std Molybdenum 1000ug/mL in 2% NH4OH
PMO2C7 500ML
EUR 386.46

ICP Std Molybdenum 10000ug/mL in 2% NH4OH
PMO4A7 100ML
EUR 231.09

ICP Std Molybdenum 10000ug/mL in 3.5% NH4OH
PMO4B4-500ML 500ML
EUR 923.06

ICP Std Molybdenum 100ug/mL in 2% NH4OH
PMO1A7 100ML
EUR 236.31

ICP Std Molybdenum 100ug/mL in 2% NH4OH
PMO1C3 500ML
EUR 364.26

AAS Molybdenum Std 1000ppm in H2O
AAMOH 500ML
EUR 106.8

AAS Molybdenum Std 10000ppm in H2O
AAMOM 500ML
EUR 338.4

Molybdenum Rod 6.0 mm diameter, 99.9+%
GX4022-250 250
EUR 167.9

Molybdenum Rod 4.0 mm diameter, 99.9+%
GX5235-250 250
EUR 120.5

Molybdenum Rod 4.0 mm diameter, 99.9+%
GX5235-500 500
EUR 163

Molybdenum Rod 3.0 mm diameter, 99.9+%
GX6474-500 500
EUR 107

Molybdenum Rod 1 mm diameter, 99.95%
GX7974-1 1
EUR 105.5

Molybdenum Rod 2.0 mm diameter, 99.9+%
GX8666-1 1
EUR 164.5

Molybdenum Rod 2.0 mm diameter, 99.9+%
GX8666-500 500
EUR 102.4

Molybdenum Rod 10 mm diameter, 99.95%
GX8980-100 100
EUR 179.3

Molybdenum Rod 10 mm diameter, 99.95%
GX8980-250 250
EUR 332.3

Molybdenum Rod 12 mm diameter, 99.9+%
GX0906-100 100
EUR 210.1

Molybdenum Rod 5.0 mm diameter, 99.95%
GX1673-100 100
EUR 114.5

Molybdenum Rod 5.0 mm diameter, 99.95%
GX1673-250 250
EUR 160.5

Molybdenum Rod 5.0 mm diameter, 99.95%
GX1673-500 500
EUR 269.6

Molybdenum Rod 20 mm diameter, 99.9+%
GX2933-100 100
EUR 303.1

Molybdenum Rod 20 mm diameter, 99.9+%
GX2933-500 500
EUR 1165.9

Molybdenum Rod 2.5 mm diameter, 99.9+%
GX3152-500 500
EUR 105.5

Molybdenum Rod 8.0 mm diameter, 99.9+%
GX3370-250 250
EUR 241.2

Molybdenum Rod 1.5 mm diameter, 99.95%
GX9336-1 1
EUR 135.6

Molybdenum Rod 30 mm diameter, 99.9+%
GX9467-100 100
EUR 536.1

Molybdenum Pellets 6 x 12 mm, 99.9+%
GX2699-100 100
EUR 198.7

Molybdenum Pellets 6 x 12 mm, 99.9+%
GX2699-25 25
EUR 99.4

Molybdenum Powder, 2-5 micron, 99.95+%
GX4223-100 100
EUR 99.4

Molybdenum Powder, 2-5 micron, 99.95+%
GX4223-500 500
EUR 277.1

Molybdenum Wire 1.0 mm diameter, 99.95%
GX4703-25 25
EUR 290

Molybdenum Wire 1.0 mm diameter, 99.95%
GX4703-5 5
EUR 119.1

Molybdenum Wire 0.3 mm diameter, 99.95%
GX7025-100 100
EUR 228.1

Molybdenum Wire 0.3 mm diameter, 99.95%
GX7025-25 25
EUR 111.5

Molybdenum Wire 0.25 mm diameter, 99.95%
GX7146-100 100
EUR 184.1

Molybdenum Wire 0.25 mm diameter, 99.95%
GX7146-25 25
EUR 96.4

Molybdenum Wire 0.7 mm diameter, 99.95%
GX7237-10 10
EUR 105.5

Molybdenum Wire 0.7 mm diameter, 99.95%
GX7237-25 25
EUR 177.5

Molybdenum Wire 0.1 mm diameter, 99.95%
GX7396-100 100
EUR 125.1

Molybdenum Wire 0.1 mm diameter, 99.95%
GX7396-50 50
EUR 90.4

Molybdenum Wire 2.0 mm diameter, 99.95%
GX0175-1 1
EUR 126.5

Molybdenum Wire 2.0 mm diameter, 99.95%
GX0175-5 5
EUR 314.4

Molybdenum Wire 1.5 mm diameter, 99.95%
GX0574-1 1
EUR 99.4

Molybdenum Wire 1.5 mm diameter, 99.95%
GX0574-5 5
EUR 224.9

Molybdenum Wire 0.5 mm diameter, 99.95%
GX3073-100 100
EUR 382.9

Molybdenum Wire 0.5 mm diameter, 99.95%
GX3073-25 25
EUR 147.6

Molybdenum Powder max. 100 micron, 99.9%
GX3538-100 100
EUR 123.5

Molybdenum Powder max. 100 micron, 99.9%
GX3538-500 500
EUR 303.1

ICP Std Molybdenum 1000ug/mL in 2-5% HNO3 tr. HF
PMO2A10 100ML
EUR 246.76

ICP Standard Molybdenum H2O 1000ug/ml
PMO2A7 100ML
EUR 132

Molybdenum Foil 0.1 mm, plane, shiny, 99.95%
GX4593-100 100
EUR 180.9

Molybdenum(IV) disulfide Nanopowder, 99 %
GX4987-10 10
EUR 311.3

Molybdenum(IV) disulfide Nanopowder, 99 %
GX4987-25 25
EUR 593.2

Molybdenum Cofactor Synthesis 2 Protein
20-abx263321
  • EUR 1930.80
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 2 µg

Molybdenum Cofactor Sulfurase (MOCOS) Antibody
abx235263-100ug 100 ug
EUR 577.2

Molybdenum Cofactor Sulfurase (MOCOS) Antibody
20-abx113870
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

Arsenic Trioxide Standard 100ppm
AR2O3-CO 1L
EUR 266.4

SULFUR TRIOXIDE PYRIDINE COMPLEX
719008 each Ask for price

Molybdenum 1000 ug/g (1000 PPM) for AA and ICP 50 grams in Base Oil 75
ORG-MO8-2Z 50G
EUR 70.8

Molybdenum 5000 ug/g (5000 PPM) for AA and ICP 50 grams in Base Oil 75
ORG-MO8-4Z 50G
EUR 85.2

Molybdenum Pellets‚6.35 x 6.35 mm, vacuum melted, 99.98%
GX9003-100 100
EUR 293.3

Molybdenum Pellets‚6.35 x 6.35 mm, vacuum melted, 99.98%
GX9003-25 25
EUR 119.1

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody
abx235264-100ug 100 ug
EUR 577.2

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody
20-abx113871
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody
20-abx322547
  • EUR 526.80
  • EUR 393.60
  • 100 ul
  • 50 ul

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody
20-abx321401
  • EUR 526.80
  • EUR 393.60
  • 100 ul
  • 50 ul

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody
20-abx321402
  • EUR 526.80
  • EUR 393.60
  • 100 ul
  • 50 ul

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody
20-abx321947
  • EUR 526.80
  • EUR 393.60
  • 100 ul
  • 50 ul

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody
abx036894-100ug 100 ug
EUR 469.2

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody
abx037731-100ug 100 ug
EUR 469.2

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody
20-abx005887
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody
20-abx135733
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody
20-abx131326
  • EUR 526.80
  • EUR 159.60
  • EUR 1479.60
  • EUR 710.40
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody
20-abx131327
  • EUR 510.00
  • EUR 159.60
  • EUR 1446.00
  • EUR 693.60
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody
20-abx304514
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody
abx028710-400ul 400 ul
EUR 627.6

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody
abx028710-80l 80 µl
EUR 343.2

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody
abx025653-400ul 400 ul
EUR 627.6

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody
abx025653-80l 80 µl
EUR 343.2

Kinesis Hollow Cathode Lamp Molybdenum 37mm Std
CHR5781 EACH
EUR 334.23

Cow Molybdenum cofactor sulfurase (MOCOS) ELISA Kit
abx516487-96tests 96 tests
EUR 1093.2

ELISA kit for Human Molybdenum cofactor sulfurase
EK3232 96 tests
EUR 663.6
Description: Enzyme-linked immunosorbent assay kit for quantification of Human Molybdenum cofactor sulfurase in samples from serum, plasma, tissue homogenates and other biological fluids.

Recombinant Molybdenum Cofactor Synthesis 1 (MOCS1)
4-RPC623Hu01
  • EUR 603.84
  • EUR 285.60
  • EUR 1934.40
  • EUR 724.80
  • EUR 1329.60
  • EUR 480.00
  • EUR 4656.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Molybdenum Cofactor Synthesis 1 expressed in: E.coli

Recombinant Molybdenum Cofactor Synthesis 1 (MOCS1)
4-RPC623Mu01
  • EUR 550.08
  • EUR 271.20
  • EUR 1732.80
  • EUR 657.60
  • EUR 1195.20
  • EUR 444.00
  • EUR 4152.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Mouse Molybdenum Cofactor Synthesis 1 expressed in: E.coli

Kinesis Hollow Cathode Lamp Molybdenum 37mm unicam
CHR5785 EACH
EUR 385.15

Kinesis Hollow Cathode Lamp Molybdenum 37mm Varian
CHR5787 EACH
EUR 385.15

Mouse Molybdenum cofactor sulfurase (MOCOS) ELISA Kit
abx516489-96tests 96 tests
EUR 886.8

Mouse Mocos/ Molybdenum cofactor sulfurase ELISA Kit
E0967Mo 1 Kit
EUR 758.4

Human MOCOS/ Molybdenum cofactor sulfurase ELISA Kit
E1626Hu 1 Kit
EUR 726

Mouse Molybdenum cofactor sulfurase, Mocos ELISA KIT
ELI-16543m 96 Tests
EUR 1038

Human Molybdenum cofactor sulfurase, MOCOS ELISA KIT
ELI-20833h 96 Tests
EUR 988.8

Human Molybdenum cofactor sulfurase (MOCOS) ELISA Kit
abx250798-96tests 96 tests
EUR 801.6

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (HRP)
20-abx304515
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Human MOCOS(Molybdenum cofactor sulfurase) ELISA Kit
EH1514 96T
EUR 681.12
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.188 ng/ml

Kinesis Hollow Cathode Lamp Molybdenum 50mm Standard
CHR5789 EACH
EUR 438.68

Bovine Molybdenum cofactor sulfurase, MOCOS ELISA KIT
ELI-19415b 96 Tests
EUR 1113.6

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (FITC)
20-abx304516
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Human Molybdenum Cofactor Synthesis 1 (MOCS1) Protein
20-abx650079
  • EUR 844.80
  • EUR 343.20
  • EUR 2598.00
  • EUR 994.80
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Molybdenum Cofactor Synthesis 1 (MOCS1) Protein
20-abx650080
  • EUR 777.60
  • EUR 326.40
  • EUR 2331.60
  • EUR 910.80
  • EUR 560.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Bovine MOCOS/ Molybdenum cofactor sulfurase ELISA Kit
E0183Bo 1 Kit
EUR 860.4

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (Biotin)
20-abx304517
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Human Molybdenum Cofactor Synthesis 2 (MOCS2) ELISA Kit
abx381488-96tests 96 tests
EUR 1093.2

SULFUR TRIOXIDE DIMETHYL FORMAMIDE COMPLEX
919007 each Ask for price

USP Stock Sol. to make Arsenic Trioxide
USP6701 100ML
EUR 124.8

USP Stock Sol. to make Arsenic Trioxide
USP6705 500ML
EUR 517.2

Mocos ELISA Kit| Mouse Molybdenum cofactor sulfurase ELISA Kit
EF015558 96 Tests
EUR 826.8

Kinesis Hollow Cathode Lamp Molybdenum 50mm PE AAnalyst (Lumina)
CHR5791 EACH
EUR 567.94

MOCOS ELISA Kit| Bovine Molybdenum cofactor sulfurase ELISA Kit
EF011614 96 Tests
EUR 826.8

Assurance Grade Molybdenum for AA and ICP 1000 ug/mL (1000 PPM) 30mL in H2O
PLMO9-2M 30ML
EUR 34.8
In conclusion, ATO can be effectively encapsulated into liposomes by remote loading method via Cu(OAc)2 gradients; the co-administration of ATO and Cu(II) via liposomal formulation may find wide applications in the treatment of various tumors.
Tags:
Arsenic trioxide enhances the chemotherapeutic efficiency of cisplatin in cholangiocarcinoma cells via inhibiting the 14-3-3ε-mediated survival mechanism
A Systematic Review Comparing Mineral Trioxide Aggregate to Other Commercially Available Direct Pulp Capping Agents in Dogs

Leave a Reply

Your email address will not be published. Required fields are marked *